Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre

• DOI: 10.3332/ecancer.2024.1654
• Publication Date: 2024-01-15T09:25:49Z
• Authors: Goutam Santosh Panda; Vanita Noronha; Vijay Patil; Amit Joshi; Nandini Menon; Rajiv Kumar; Trupti Pai; Omshree Shetty; Amit Janu; Nivedita Chakrabarty; Nilendu Purandare; Sayak Dey; Kumar Prabhash

Introduction: ROS1 as a driver mutation is observed in approximately 1%-2% of all nonsmall cell lung cancer (NSCLC).Given its rarity, we share our experience regarding ROS1positive NSCLC including the access to tyrosine kinase inhibitors (TKIs) lowmiddle income country like India. Methods:It retrospective analysis ROS1-positive patients registered between January 2015 December 2021 for demographics, treatment patterns and outcomes i.e., overall survival (OS) progression free (PFS).Results: Baseline characteristics were available 70 78 positive by fluorescent situ hybridisation.Median age at presentation was 52 years, 39 (55.7%) males, most (51, 72.86%) non-smokers ten (14.3%) had poor Eastern Cooperative Oncology Group (ECOG) performance status (PS) PS >2 presentation.A total 67 receiving directed therapy analysed survival.The first line (1L) therapies included -ROS1 TKIs 38, chemotherapy 20, epidermal growth factor receptor TKI eight chemotherapy-bevacizumab one only.ROS1 provided 20 part an assistance programme.The median OS who received not attained (95% CI 37.85-NA), while it 8.11 6.31-NA) months those did (HR-0.1673).The PFS 1L compared no-TKI group 27.07 24.28-NA) versus 5.78 3.42-12) (HR: 0.2047).Poor ECOG only independent prognosticator survival. Conclusion:Using improves clinical all-comers though statistically significant.To further improve outcomes, future trials should pay special attention with find way increase current limited TKI.